Literature DB >> 30093112

The miR-15b-5p/PDK4 axis regulates osteosarcoma proliferation through modulation of the Warburg effect.

Yiping Weng1, Yifei Shen1, Yunjie He2, Xiaohui Pan1, Jingwen Xu3, Yuqing Jiang1, Qiang Zhang1, Shenyu Wang1, Fanqi Kong4, Shujie Zhao4, Dong Zhou5, Yunkun Zhang6.   

Abstract

Blocking aerobic glycolysis has been proposed as an attractive therapeutic strategy for impairing the proliferation of cancer cells. However, the underlying mechanisms are poorly understood. Here, we show that miR-15b-5p was downregulated in osteosarcoma (OS) and that lower expression of miR-15b-5p promoted proliferation and contributed to the Warburg effect in OS cells. Mechanistically, miR-15b-5p acted as a tumor suppressor in OS by directly targeting pyruvate dehydrogenase kinase-4 and inhibiting its expression. These results reveal a previously unknown function of miR-15b-5p in OS, which is associated with metabolic alterations that promote cancer progression. miR-15b-5p may play an essential role in the molecular therapy of patients with OS.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Osteosarcoma; PDK4; Proliferation; Warburg effect; miR-15b-5p

Mesh:

Substances:

Year:  2018        PMID: 30093112     DOI: 10.1016/j.bbrc.2018.08.035

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

Review 1.  Engineering Multidimensional Evolutionary Forces to Combat Cancer.

Authors:  Caroline E McCoach; Trever G Bivona
Journal:  Cancer Discov       Date:  2019-04-16       Impact factor: 39.397

2.  MicroRNAs and Heat Shock Proteins in Breast Cancer Biology.

Authors:  Mehmet Taha Yildiz; Lütfi Tutar; Nazlı Irmak Giritlioğlu; Banu Bayram; Yusuf Tutar
Journal:  Methods Mol Biol       Date:  2022

3.  microRNA-15b-5p shuttled by mesenchymal stem cell-derived extracellular vesicles protects podocytes from diabetic nephropathy via downregulation of VEGF/PDK4 axis.

Authors:  Tiantian Zhao; Qingsong Jin; Lili Kong; Dongdong Zhang; Yaqin Teng; Liangyan Lin; Xiaoyan Yao; Yongjun Jin; Minglong Li
Journal:  J Bioenerg Biomembr       Date:  2021-11-22       Impact factor: 2.945

4.  TRPM2-AS promotes the malignancy of osteosarcoma cells by targeting miR-15b-5p/PPM1D axis.

Authors:  Yingchun Cai; Yudan Yang; Xudong Zhang; Qingqing Ma; Mengyi Li
Journal:  Cell Cycle       Date:  2022-01-31       Impact factor: 5.173

5.  miR-16-5p/PDK4-Mediated Metabolic Reprogramming Is Involved in Chemoresistance of Cervical Cancer.

Authors:  Zhao Zhao; Mei Ji; Qianqing Wang; Nannan He; Yue Li
Journal:  Mol Ther Oncolytics       Date:  2020-05-23       Impact factor: 7.200

6.  S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma.

Authors:  Yifei Shen; Shujie Zhao; Shenyu Wang; Xiaohui Pan; Yunkun Zhang; Jingwen Xu; Yuqing Jiang; Haibo Li; Qiang Zhang; Jianbo Gao; Qin Yang; Yang Zhou; Shuheng Jiang; Huilin Yang; Zhigang Zhang; Rong Zhang; Jun Li; Dong Zhou
Journal:  EBioMedicine       Date:  2018-12-23       Impact factor: 8.143

7.  miR-15b enhances the proliferation and migration of lung adenocarcinoma by targeting BCL2.

Authors:  Jun Wang; Shupeng Yao; Yanping Diao; Yan Geng; Yanling Bi; Guangyue Liu
Journal:  Thorac Cancer       Date:  2020-03-27       Impact factor: 3.500

8.  LncRNA KCNQ1OT1 sponges miR-34c-5p to promote osteosarcoma growth via ALDOA enhanced aerobic glycolysis.

Authors:  Yifei Shen; Jingwen Xu; Xiaohui Pan; Yunkun Zhang; Yiping Weng; Dong Zhou; Shisheng He
Journal:  Cell Death Dis       Date:  2020-04-24       Impact factor: 8.469

9.  miR-1297 Suppresses Osteosarcoma Proliferation and Aerobic Glycolysis by Regulating PFKFB2.

Authors:  Xiaohui Pan; Haibo Li; Jingxue Tan; Xiaokun Weng; Li Zhou; Yiping Weng; Xiaojian Cao
Journal:  Onco Targets Ther       Date:  2020-11-03       Impact factor: 4.147

10.  MiR-5683 suppresses glycolysis and proliferation through targeting pyruvate dehydrogenase kinase 4 in gastric cancer.

Authors:  Yongchang Miao; Qing Li; Guangli Sun; Lu Wang; Diancai Zhang; Hao Xu; Zekuan Xu
Journal:  Cancer Med       Date:  2020-08-11       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.